As several GLP-1 receptor agonists have been licensed for the treatment of diabetes and obesity, they were also evaluated in patients with MASH, and successful phase 2a and 2b studies have resulted in progression to phase 3 clinical trials [37]. This evidence concerns the gene GLP1R and metabolic dysfunction-associated steatohepatitis.